PFIZER INC (PFE)
US7170811035 - Common Stock
Cramer's Lightning Round: 'I'm not a buyer' of NIO
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
FDA to decide on approving Keytruda/Padcev combo therapy by May 9 (NYSE:MRK)
The FDA has accepted Merck's (MRK) application for approval of its drug Keytruda in combination with Seagen (SGEN) and Astellas’s Padcev for the treatment of urothelial cancer.
UPDATE 1-Pfizer is sued by Texas over COVID vaccine claims
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective.
‘Pursuing justice’: Texas sues Pfizer for overstating COVID-19 vaccine effectiveness
The pharmaceutical giant sought to “intimidate and silence” those who questioned the product’s efficacy, the lawsuit alleges.
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless.
Pfizer is sued by Texas over COVID-19 vaccine claims
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and that the pandemic got worse even after people started taking Pfizer's vaccine.
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment (Anti-Allergy Drugs, Immunotherapy) by Route of Administration (Oral, Inhalation, Intranasal, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA)
Texas Sues Pfizer for Overstating Covid-19 Vaccine Effectiveness
Texas Attorney General Ken Paxton accused Pfizer Inc. of misrepresenting the effectiveness of the company’s COVID-19 vaccine in a lawsuit filed in state court on Thursday.
Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PFE January 2024 Options Begin Trading
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Texas AG Sues Pfizer Over Covid Vaccine Effectiveness
Attorney General Ken Paxton alleges Pfizer also attempted to silence critics of its vaccine.
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.
4 Large Drug Stocks to Watch as IBD Market Gains Traction
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
New Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry
CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the beauty and life science industries today announced their partnership to offer our customers additional value-add services."We are absolutely thrilled about the incredible opportunities that this partnership brings to the table!" comments Patrick Windsor, Managing Director of Risetime. "By harnessing Risetime's exceptional expertise in FDA regulation and seamlessly integrating it with the cutting-edge CARA Platform, we're setting the stage for an extraordinary level of support to the Cosmetic and Beauty industries, ensuring their complete compliance with MoCRA regulations like never before!"The key focus of this partnership will be the configuration of the CARA Platform for the Cosmetic and Beauty industries and support of the current MoCRA FDA regulations. As a data and content management platform, CARA helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes and remain compliant. The unified CARA Life Sciences Platform™ is the pre-configured, out-of-the-box layer with standardised apps for Regulatory, Quality, Safety, and Clinical processes, powered by a single structured data lake that gives users instant access to cross-functional data and enables powerful process optimisation for pharmaceutical companies. This partnership will allow Generis to further expand and fine-tune their offering for the Cosmetics industry."Our partnership with Risetime is a very exciting opportunity." commented James Kelleher, CEO of Generis. "Our CARA Platform provides rich functionality for companies across all regulated industries to remain compliant and keep up with the changing regulations, and with the expertise and guidance provided by the Risetime we can ensure that customers are thriving and improving the way their organisation works."About RisetimeRisetime is a Chicago-based service provider that offers exceptional services to clients across diverse industries with our skilled personnel and robust infrastructure.Our Digital Content Managers use their elevated understanding of healthcare and pharmaceutical industry requirements, to handle assets and metadata correctly in an FDA regulated industry.More at risetime.comAbout GenerisGeneris is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com.
Eight Beaten-Down Stocks Including Pfizer and Hasbro That Look Like Bargains
Some of the stocks dumped as funds do tax-loss selling can be attractive buys.
AWS expands cloud, AI relationship with big pharma players Pfizer, Amgen
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
Pfizer disappointed in RSV shot's market share, CFO says
Pfizer Inc is disappointed in its performance versus rival GSK in the RSV vaccine market and is working to pick up market share in 2024, Chief Financial Officer David Denton said on Tuesday. Reuters reported in October that Pfizer's shot was lagging behind the GSK vaccine, which accounted for close to two-thirds of RSV shots given in the U.S. since early September. "If you look at our market share, I don't think we performed as well as we thought we could, or we think we will going forward," Denton told investors at a conference hosted by Evercore ISI analysts.
Pfizer CFO reiterates Seagen closing expected later this year, early next year
Pfizer CFO reaffirms expectations for closing the $43 billion Seagen acquisition, awaiting approval from the Federal Trade Commission.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
UPDATE 1-WHO authorizes emergency use of Novavax's updated COVID vaccine
Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday. The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for much of this year but has since been overtaken by other variants as the virus evolves. Novavax missed out on the COVID-19 vaccine windfall, which benefited rivals, due to manufacturing issues that delayed its filing for approval during the peak of the pandemic.
3 Top-Rated Value Stocks That Analysts Are Loving Now
Stuff your stockings with these top-rated value stocks. Analysts are feeling good about this value stocks heading into 2024.
Rishi Sunak bids to drum up foreign investment at Hampton Court summit
PM and chancellor will meet heads of firms including Goldman Sachs, Blackstone and JP Morgan
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by End User (Hospitals, Specialty Centers) and by Geography (North America, South America, Europe, Asia Pacific, MEA)
Is Pfizer Stock a Buy Now?
The company keeps falling out of favor with the market.
Uncovering Dividend Opportunities with NYSE:PFE.
Balancing Dividends and Fundamentals: The Case of PFIZER INC (NYSE:PFE).
These S&P500 stocks are the most active in today's session
Let's have a look at the most active S&P500 stocks in today's session.
What's going on in today's session: S&P500 most active stocks
Stay informed about the most active stocks in the S&P500 index on Monday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Most active S&P500 stocks in Friday's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Friday. Discover the stocks that are generating the highest trading volume and driving market activity.